From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists were able to identify ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

AI predicts Parkinson’s disease using medical and prescription data, enhancing early diagnosis and research into new ...

Advancing Light Therapy Research to Enhance Quality of Life for Parkinson's Patients This trial is important becau ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

21, 2025 — The B vitamin mitigates manganese neurotoxicity, which produces symptoms ... motor function, offering a new therapeutic ... A Risky Business: Why Do Some Parkinson's Disease ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

“As the motor symptoms of Parkinson’s disease worsen over time ... Tell your healthcare provider about all the medicines you take, including prescription and non-prescription (over-the-counter) ...